May 15 2026
Fed. Cir. 24-2089 Panel Decision

MCOM IP, LLC v. City National Bank of Florida

The United States Court of Appeals for the Federal Circuit affirmed a district court dismissal of a patent infringement complaint but reversed an award of attorneys fees and a sanction against the plaintiff and its counsel. The appellate court held that the patent claims were invalid for obviousness but found the lower court lacked sufficient grounds to deem the case exceptional or the litigation conduct in bad faith.

May 15 2026
Fed. Cir. 25-1215 Panel Decision

Perdiemco LLC v. Nextraq LLC

The United States Court of Appeals for the Federal Circuit affirmed the lower court's judgment in a civil dispute between Perdiemco LLC and Nextraq LLC. The court issued a nonprecedential per curiam order under Federal Circuit Rule thirty-six.

May 15 2026
Fed. Cir. 24-1828 Panel Decision

MCOM IP, LLC v. HSBC Bank USA, N.A.

The United States Court of Appeals for the Federal Circuit affirmed a dismissal of a patent infringement complaint against a major bank. The court held that the plaintiff was barred from asserting the patent claim due to issue preclusion and failed to plausibly allege infringement.

May 13 2026
Fed. Cir. 24-1641 Panel Decision

Actelion Pharmaceuticals Ltd v. Mylan Pharmaceuticals Inc

The United States Court of Appeals for the Federal Circuit affirmed a district court ruling that Mylan Pharmaceuticals did not infringe Actelion Pharmaceuticals' patents for a stable epoprostenol drug formulation. The court held that the patent claim term requiring a pH of thirteen or higher refers to measurements taken at standard temperature, and that Actelion was barred from asserting infringement by equivalence.